NC
ADVM

nVerses Capital’s Adverum Biotechnologies ADVM Stock Holding History

nVerses Capital’s Portfolio ADVM Stock Details ADVM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-1,600
Closed -$11.2K – 14
2024
Q3 		$11.2K Buy
+1,600
New +$11.6K 0.01% 875

Other funds holding ADVM

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PWA
Principia Wealth Advisory Dallas, Texas $160M AUM 37.01% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

nVerses Capital's ADVM Position: Q4 2024 in Review

nVerses Capital sold out of Adverum Biotechnologies (ADVM) in Q4 2024, closing a stake of 1,600 shares — an estimated $11.2K sold.

nVerses Capital first reported a position in ADVM in Q3 2024 and held it in 1 quarter. The position peaked at $11.2K in Q3 2024. 69 funds tracked by Wall St. Rank hold ADVM as of Q4 2024.

  • nVerses Capital reported no remaining Adverum Biotechnologies position as of Q4 2024 after selling out during the quarter.
  • nVerses Capital sold 1,600 Adverum Biotechnologies shares in Q4 2024, an estimated $11.2K.
  • nVerses Capital first reported a position in Adverum Biotechnologies in Q3 2024 and held it in 1 quarter.
  • nVerses Capital's Adverum Biotechnologies position peaked at $11.2K in Q3 2024.
  • 69 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q4 2024.

Based on nVerses Capital's 13F filing for Q4 2024.